EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer

Roger Ferreira, Kassandra R. Bisson, Andrea Beharry, Champica Nicholas, Marco Iafolla, Samir Bidnur, Brandon S. Sheffield

Journal of Molecular Pathology · 04.06.2026 · 7 (2) · 22

DOI: 10.3390/jmp7020022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Molecular Pathology, online erschienen am 04.06.2026. Verfasst von Roger Ferreira und 6 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Ataxia telangiectasia-mutated kinase is encoded by the ATM gene. This gene is altered in many cancer types; however, it is most relevant for eligibility of poly-ADP-ribose polymerase inhibitor (PARPi) therapy in metastatic castrate-resistant prostate cancer in Canada. Non-benign ATM alterations are relatively uncommon, seen in less than 10% of prostate cancers; however, many of these are variants of uncertain significance with limited evidence of clinical significance or actionability.

Methods

To aid in variant classification of next-generation sequencing results, ATM immunohistochemistry (IHC) is performed on patient tumour samples to serve as patient-specific functional evidence for ATM protein loss.

Results

ATM IHC demonstrates strong concordance with known loss-of-function variants and copy number losses. Additionally, it can be used to clarify ATM protein loss in cases involving variants of uncertain significance (VUSs) or copy number deletions.

Conclusions

Incorporation of ATM IHC into clinical testing for prostate cancer represents a relatively cost-effective orthogonal approach that can rescue poor-quality NGS results and clarify the functional impact of ATM VUSs on protein expression. Overall, this strategy may provide useful supportive evidence in prostate cancer biomarker testing and interpretation.

Zitieren

APA

Ferreira, R., Bisson, K. R., Beharry, A., Nicholas, C., Iafolla, M., Bidnur, S., & Sheffield, B. S. (2026). ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer. Journal of Molecular Pathology, 7(2), 22. https://doi.org/10.3390/jmp7020022

Vancouver

Ferreira R, Bisson KR, Beharry A, Nicholas C, Iafolla M, Bidnur S, et al. ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer. Journal of Molecular Pathology. 2026;7(2):22. doi:10.3390/jmp7020022

BibTeX
@article{Ferreira2026,
  author = {Ferreira, Roger and Bisson, Kassandra R. and Beharry, Andrea and Nicholas, Champica and Iafolla, Marco and Bidnur, Samir and Sheffield, Brandon S.},
  title = {ATM Immunohistochemistry as a Tool to Identify and Classify Somatic ATM Variants in Prostate Cancer},
  journal = {Journal of Molecular Pathology},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {22},
  doi = {10.3390/jmp7020022}
}
Kostenlos starten →